Dianthus Therapeutics, Inc. - Common Stock DNTH 深 沪
等待开盘 09-23 09:30:00 美东时间
37.76
+1.010
+2.75%
华盛通- 最 高39.473
- 今 开37.99
- 成交量 56.42万股
- 最 低 36.365
- 昨 收 36.75
- 总市值 15.03亿
- 52周最高 39.865
- 市盈率 静 --
- 换手率 1.42%
- 52周最低 13.365
- 委 比 45.29%
- 总股本 3980.44万
- 历史最高 336.00
- 量 比 0.63
- 振 幅 8.46%
- 历史最低 5.136
- 每 手 1
- 风险率 4.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
Clear Street Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $100
Clear Street analyst Bill Maughan initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $100.
09-17 21:45
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
Dianthus Therapeutics Raises $270M Through Stock Offering
The latest announcement is out from Dianthus Therapeutics ( ($DNTH) ). On Septe...
09-11 19:48
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
Dianthus Therapeutics prices upsized $251M securities offering
Dianthus Therapeutics (NASDAQ:DNTH) has priced its recently announced and upsized public offering, raising approximately $251 million in gross proceeds, by selling 6.49 million shares of common stock ...
09-10 15:10
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
Dianthus Therapeutics raised approximately $251 million through an upsized public offering of 6,487,879 shares of common stock at $33.00 per share, with an additional option for underwriters to purchase up to 1,140,000 more shares. The company aims to use the net proceeds to advance its preclinical and clinical development, as well as for general corporate purposes. The offering is set to close on September 11, 2025, subject to customary closing ...
09-10 02:35
Analyst Expectations For Dianthus Therapeutics's Future
In the preceding three months, 4 analysts have released ratings for Dianthus Th...
09-09 22:01
Dianthus Therapeutics launches $150M underwritten public offering
Dianthus Therapeutics (NASDAQ:DNTH) has commenced an underwritten public offering of $150M of its shares of its common stock, pre-funded warrants to purchase shares of its common stock. Dianthus inten...
09-09 04:07
Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile
Dianthus Therapeutics announced positive results from the Phase 2 MaGic trial of claseprubart (DNTH103) for generalized Myasthenia Gravis (gMG). Both 300mg and 600mg Q2W doses achieved statistically significant and clinically meaningful improvements in MG-ADL and QMG scores at Week 13, with rapid onset of action at Week 1. The 300mg dose also showed significant improvements across MSE, MGC, and MG-QoL-15r scores. Claseprubart demonstrated a favor...
09-08 11:00
